Xtant (XTNT) Director Stavros Vizirgianakis Receives 323,275-Share DSU Award

What Happened
Stavros G. Vizirgianakis, a director of Xtant Medical Holdings, was granted 323,275 deferred stock units (DSUs) on August 15, 2026. The award was granted at $0.00 per share (no cash exchanged), so the immediate reported value is $0. Each DSU represents a contingent right to receive one share of Xtant common stock. The DSUs vest on August 15, 2027, conditioned on the reporting person remaining a director through that date; settlement of vested DSUs is deferred to a later date under the DSU award agreement.

Key Details

• Transaction date: 2026-08-15; Filing date: 2026-08-18.
• Grant: 323,275 DSUs at $0.00 (reported value $0).
• Vesting/condition: Vest on 2027-08-15 if the reporting person remains a director. Settlement of vested shares is deferred per the DSU agreement.
• Shares issuable after transaction: filing notes 1,843,491 shares issuable upon settlement of DSUs granted under the 2023 Equity Incentive Plan (this total includes the 323,275 awarded on 8/15/2026).
• Footnotes: F1 describes the DSU vesting and deferred settlement terms; F2 notes the 1,843,491 shares issuable upon DSU settlement.
• No indication of a sale, purchase, or option exercise—this is an equity compensation grant to a director.

Context
DSUs are a form of deferred equity compensation: they give the holder a contingent right to receive shares in the future rather than immediate stock ownership. Such grants are common for director compensation and do not by themselves indicate the insider is buying or selling shares in the open market.